Dynavax Technologies Corporation [DVAX] stock is trading at $10.24, up up 1.69%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DVAX shares have lost -11.03% over the last week, with a monthly amount drifted -12.78%, and not seem to be holding up well over a long-time horizon.
On 20, September 2022, Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate. In a post published today on Yahoo Finance, Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced that Clover’s contract development and manufacturing organization (CDMO) has received a European Union Good Manufacturing Practice (EU GMP) certificate for the production of Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). The EU GMP certificate is in connection with Clover’s regulatory submission to the European Medicines Agency (EMA) and follows a successful inspection of the CDMO site by the Ireland Health Products Regulatory Authority. It signifies that the production of SCB-2019 meets the EU’s standards for quality and safety.
From an analyst’s perspective:
Previously, Goldman started tracking the stock with Buy rating on August 06, 2021, and set its price target to $19. On August 07, 2020, H.C. Wainwright reiterated its Buy rating and revised its price target to $12 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $14 on August 03, 2020. Evercore ISI initiated its recommendation with a Outperform and recommended $14 as its price target on June 15, 2020. H.C. Wainwright started tracking with a Buy rating for this stock on October 18, 2019, and assigned it a price target of $13. In a note dated July 11, 2019, Cantor Fitzgerald upgraded an Overweight rating on this stock but restated the target price of $20.
Dynavax Technologies Corporation [DVAX] stock has fluctuated between $7.26 and $21.39 over the past year. Currently, Wall Street analysts expect the stock to reach $25.50 within the next 12 months. Dynavax Technologies Corporation [NASDAQ: DVAX] shares were valued at $10.24 at the most recent close of the market. An investor can expect a potential return of 149.02% based on the average price forecast.
Analyzing the DVAX fundamentals
Dynavax Technologies Corporation [NASDAQ:DVAX] reported sales of 256.46 billion for the most recent quarter, which represents a growth of 385.80%. Gross Margin for this corporation currently stands at +60.28% with Operating Margin at +30.43%, Pretax Margin comes in at +17.74%, and Net Margin reading is +16.51%.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.92 points at the first support level, and at 9.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.44, and for the 2nd resistance point, it is at 10.65.
Dynavax Technologies Corporation [DVAX] reported earnings per share of $0.22 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.24/share, meaning a difference of $-0.02 and a surprise factor of -8.30%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were $0.55 per share as compared to estimates of $0.64 per share, a difference of $-0.09 representing a surprise of -14.10%.
Ratios To Look Out For
For context, Dynavax Technologies Corporation’s Current Ratio is 2.80. In addition, the Quick Ratio stands at 1.64 and the Cash Ratio stands at 0.98. Considering the valuation of this stock, the price to sales ratio is 4.28, the price to book ratio is 7.78 and the P/E (TTM) ratio is 7.64.
Transactions by insiders
In the past 3 months, 8 insiders have purchased 113,685 shares, and 9 have sold 3,108,131 shares. Recent insider trading involved Hack Andrew A. F., Director, that happened on Aug 15 when 3.0 million shares were sold. Senior Vice President, Janssen Robert completed a deal on Aug 09 to sell 7938.0 shares. Meanwhile, President & COO Novack David F sold 26250.0 shares on Aug 09.